StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note released on Tuesday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Eagle Pharmaceuticals stock opened at $0.42 on Tuesday. The stock’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $2.87. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.81.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mackenzie Financial Corp bought a new position in Eagle Pharmaceuticals in the 2nd quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $65,000. Fidelis Capital Partners LLC bought a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $71,000. Vanguard Personalized Indexing Management LLC bought a new position in Eagle Pharmaceuticals in the second quarter valued at approximately $76,000. Finally, RBF Capital LLC raised its position in Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after purchasing an additional 14,991 shares in the last quarter. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.